Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

A looming $300 billion patent cliff by 2030 is spurring a surge in biotech M&A, with March 2026 alone seeing $31.5 billion in deals. Analysts highlight CRISPR Therapeutics, Intellia Therapeutics, and ...

Scientists have announced two major advances: a self-assembling polymer system that improves non-viral gene delivery and a DNA-based molecular computer that combines processing and memory at nanoscale ...

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion. A key reason for this activity is the ...

Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with ...

April 27 DNA Day” Youth Forum was held in Baku, gathering scientists, geneticists, and young researchers to mark DNA Day and ...

In light of increased interest in the capabilities of biotechnology worldwide, those who took part in the Youth DNA Forum in ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

Posters detail large gene insertion and epigenetic editing capabilities, expanding ElevateBio’s gene editing toolbox– Additional presentations ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...